Join OncLive science summit on lung cancer with our oncology experts, Nov. 17

October 25, 2022 Providence Provider Update News Team

Share this Article
Facebook
Twitter
LinkedIn

Photo courtesy OncLive

PROVIDENCE CANCER INSTITUTE – Caregivers and providers are invited to join a free, in-person summit featuring some of our own oncology experts in downtown Portland.

OncLive, in partnership with Providence Cancer Institute, will host State of Science Summit: Lung Cancer on Nov. 17. OncLive is a leading digital provider of resources and information to oncology professionals.

This summit will cover new cancer treatment approaches, research and strategies. Featured speakers include Providence oncology experts Rachel Sanborn, M.D., Evelyn Brosnan, M.D., Regan M. Duffy, M.D., and Michael D. Skokan, M.D.

Dr. Sanborn, medical director, Providence Thoracic Oncology Program, will chair the event.

State of Science Summit: Lung Cancer
6-9 p.m.
Thursday, Nov. 17
The Benson Hotel
309 S.W. Broadway, Portland
Register online

Safety precautions will be implemented for the event, including single-use, disposable surgical masks available at check-in, social distancing measures for attendees, and a designated COVID compliance representative available to address any other personal protection concerns.

Learn more

For more details, go to event.onclive.com.

Long COVID: What is it and how long will it last?

A recent Hear Me Now podcast examines research about long COVID and what the evidence shows.

Providence study reveals high incidence of chronic kidney disease in diabetes beset by disparities

Study reveals a concerningly high incidence chronic kidney disease (CKD) in people with diabetes that was m...

Other content in this Stream

Prostate cancer study includes a tumor test to personalize treatment

Join OncLive science summit on lung cancer with our oncology experts, Nov. 17

Learn more

Previous Article

Next Article

Other content in this Stream

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Learn about dysautonomia, its symptoms, and how it's connected to long COVID. Discover treatment options and expert insights at Providence.

A research collaboration between CORE, PSU researcher Dr. Roberta Hunte and the Healthy Birth Initiative (HBI), is studying the impact of a cross-sector partnership on Black maternal health outcomes.

A novel peptide vaccine against glioblastoma, a deadly brain tumor, is offering hope to some patients thanks to the work of an international effort including Providence's Santosh Kesari, MD, PhD.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

The procedure using the new TriClip to repair a leaky tricuspid valve was also a first in the Pacific Northwest.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A first-of-its-kind study on the efficacy and safety of weight loss medications in the real world is helping to provide clinicians with new is helping to provide clinicians with valuable new evidence.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

Over the next three years, this study seeks to identify the patterns of access and use of cancer services among high-risk patients to understand how to guide them toward quality care.

Providence researchers conducted over 2400 studies in 2023, according to the 2023 Providence Research Network Annual Report

Learn more about a clinical trial for men with metastatic prostate cancer.

In North Puget Sound, Providence Swedish has implemented solutions to address opioid overdoes, including participating in grant programs and research to discover addiction treatments that work.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

The largest study of angiosarcoma published to date, co-authored at Providence, describes the incidence and presentation patterns of angiosarcoma, a rare but potentially deadly cancer.

The 2023 Providence Research Network annual report, released on Clinical Trials Day 2024, highlights the breadth and impact of research at Providence.